首页> 外文期刊>World Journal of Gastroenterology >Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
【24h】

Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.

机译:台湾慢性丙型肝炎患者和非酒精性脂肪肝患者的HFE突变患病率及其与血清铁水平的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To assess the prevalence of the two mutations, C282Y and H63D of HFE gene, in healthy subjects, patients with chronic hepatitis C (CHC), and patients with nonalcoholic fatty liver disease (NAFLD) in Taiwan and to explore the contribution of the HFE mutation on serum iron stores in CHC and NAFLD groups. METHODS: We examined C282Y and H63D mutations of HFE gene in 125 healthy subjects, 29 patients with CHC, and 33 patients with NAFLD. The serum iron markers, including ferritin, iron, and total iron binding capacity (TIBC), were assessed in all patients. RESULTS: All of the healthy subjects and patients were free from C282Y mutation. The prevalence of H63D heter-ozygosity was 4/125 (3.20%) in healthy subjects, 2/29 (6.90%) in CHC group, and 1/33 (3.03%) in NAFLD group. The healthy subjects showed no significant difference in the prevalence of H63D mutation as compared with the CHC or NAFLD group. Increased serum iron store was found in 34.48% of CHC patients and 36.36% of NAFLD patients. In three patients of H63D heterozygosity, only one CHC patient had increased serum iron store. There was no significant difference in the prevalence of HFE mutations between patients with increased serum iron store and those without in CHC or NAFLD group. CONCLUSION: The HFE mutations may not contribute to iron accumulation in the CHC or NAFLD group even when serum iron overload is observed in more than one-third of these patients in Taiwan.
机译:目的:评估健康受试者,慢性丙型肝炎(CHC)患者和台湾非酒精性脂肪肝疾病(NAFLD)患者中HFE基因的两个突变C282Y和H63D的患病率,并探讨其贡献CHC和NAFLD组血清铁储库的HFE突变。方法:我们在125名健康受试者,29名CHC患者和33名NAFLD患者中检查了HFE基因的C282Y和H63D突变。在所有患者中评估血清铁标志物,包括铁蛋白,铁和总铁结合能力(TIBC)。结果:所有健康受试者和患者均无C282Y突变。健康受试者中H63D杂合性的患病率为4/125(3.20%),CHC组中为2/29(6.90%),NAFLD组中为1/33(3.03%)。与CHC或NAFLD组相比,健康受试者的H63D突变患病率无明显差异。在CHC患者中34.48%和NAFLD患者中血清铁存储增加。在三名H63D杂合性患者中,只有一名CHC患者的血清铁存储增加。血清铁储存增加的患者与CHC或NAFLD组的患者相比,HFE突变的患病率无显着差异。结论:即使在台湾超过三分之一的患者中观察到血清铁超负荷,HFE突变也可能不会在CHC或NAFLD组中促进铁蓄积。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号